Understanding the tumor microenvironment in head and neck squamous cell carcinoma.

Autor: Rad HS; University of Queensland Diamantina Institute the University of Queensland Brisbane QLD Australia., Shiravand Y; Department of Molecular Medicine and Medical Biotechnology University of Naples Federico II Naples Italy., Radfar P; School of Biomedical Engineering University of Technology Sydney Sydney NSW Australia., Ladwa R; University of Queensland Diamantina Institute the University of Queensland Brisbane QLD Australia.; Princess Alexandra Hospital Brisbane QLD Australia., Perry C; University of Queensland Diamantina Institute the University of Queensland Brisbane QLD Australia.; Princess Alexandra Hospital Brisbane QLD Australia., Han X; Department of Biomedical Science University of the Pacific, Arthur A. Dugoni School of Dentistry Stockton CA USA., Warkiani ME; School of Biomedical Engineering University of Technology Sydney Sydney NSW Australia.; Institute of Molecular Medicine Sechenov First Moscow State University Moscow Russia., Adams MN; Centre for Genomics and Personalised Health School of Biomedical Sciences Queensland University of Technology Brisbane QLD Australia., Hughes BG; University of Queensland Diamantina Institute the University of Queensland Brisbane QLD Australia.; Royal Brisbane and Women's Hospital Brisbane QLD Australia., O'Byrne K; Princess Alexandra Hospital Brisbane QLD Australia.; Centre for Genomics and Personalised Health School of Biomedical Sciences Queensland University of Technology Brisbane QLD Australia., Kulasinghe A; University of Queensland Diamantina Institute the University of Queensland Brisbane QLD Australia.
Jazyk: angličtina
Zdroj: Clinical & translational immunology [Clin Transl Immunology] 2022 Jun 06; Vol. 11 (6), pp. e1397. Date of Electronic Publication: 2022 Jun 06 (Print Publication: 2022).
DOI: 10.1002/cti2.1397
Abstrakt: Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors. While significant progress has been made using multimodal treatment, the 5-year survival remains at 50%. Developing effective therapies, such as immunotherapy, will likely lead to better treatment of primary and metastatic disease. However, not all HNSCC tumors respond to immune checkpoint blockade therapy. Understanding the complex cellular composition and interactions of the tumor microenvironment is likely to lead to new knowledge for effective therapies and treatment resistance. In this review, we discuss HNSCC characteristics, predictive biomarkers, factors influencing immunotherapy response, with a focus on the tumor microenvironment.
Competing Interests: The authors declare no conflict of interest.
(© 2022 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje